Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date:    Thursday, February 25, 2021
Time:   8:30 am Eastern Time
Domestic Dial-in:     877-423-9813
International Dial-in:       201-689-8573
Conference ID:   13716171

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit

Investor & Media Contacts:

Will Brown Stacey Jurchison
Chief Financial Officer                                    Sr. Dir, Investor Relations
Phone: 240-654-1450      Phone : 410-474-8200 

error: Content is protected !!